DrugBiological
flt3 ligand protein clinical trials
Includes 10 studies of CDX-301.
Keep track of what changes. Save the flt3 ligand protein studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 1998 | 2 |
| 2000 | 1 |
| 2001 | 1 |
| 2011 | 1 |
| 2014 | 4 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 14
National Cancer Institute (NCI) (3) · Celldex Therapeutics (3) · Ashutosh Kumar Tewari (1) · Icahn School of Medicine at Mount Sinai (1) · Montefiore Medical Center (1) · Parker Institute for Cancer Immunotherapy (1) · Joshua Brody (1) · Eastern Cooperative Oncology Group (1)
Often tested with
Tested in the same studies.
Poly ICLC (3) · CDX-1140 (2) · Pembrolizumab (1) · Fms-Related Tyrosine Kinase 3 Ligand (1) · Bempegaldesleukin (1) · DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151 (1) · Glembatumumab vedotin (1) · Varlilumab (1)
Studies
Open first, then newest update. How each study uses flt3 ligand protein is read from its arms, and is right about nine times in ten.
Testing it · 17
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerRecruitingPhase 1University of Texas Southwestern Medical CenterNCT05029999Written as CDX-301
- Converting HR+ Breast Cancer Into an Individualized VaccineRecruitingPhase 2Weill Medical College of Cornell UniversityNCT03804944Written as CDX-301
- Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedPhase 1/2Icahn School of Medicine at Mount SinaiNCT03789097Written as Flt3L
- FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung CancerCompletedPhase 2Montefiore Medical CenterNCT02839265Written as FLT3 Ligand Therapy (CDX-301)
- The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.Active, not recruitingPhase 1Ashutosh Kumar TewariNCT05010200Written as CDX-301
- Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer PatientsTerminatedPhase 2Washington University School of MedicineNCT04536077Written as CDX-301
- Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsCompletedPhase 1Parker Institute for Cancer ImmunotherapyNCT03835533Written as CDX-301 (Cohort B and C)
- flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell CancerCompletedPhase 2National Cancer Institute (NCI)NCT00019396Written as flt3 ligand
- FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic RadiotherapyTerminatedPhase 1/2Albert Einstein College of MedicineNCT04491084Written as FLT3 Ligand (CDX-301)
- In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose RadiotherapyCompletedPhase 1/2Joshua BrodyNCT01976585Written as rhuFlt3L/CDX-301
- A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT02129075Written as Recombinant Flt3 Ligand
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedPhase 2Celldex TherapeuticsNCT02302339Written as glembatumumab vedotin and CDX-301
- A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy VolunteersCompletedPhase 1Celldex TherapeuticsNCT01465139Written as CDX-301
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedPhase 2Celldex TherapeuticsNCT02200380Written as CDX-301
- Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedPhase 1National Cancer Institute (NCI)NCT00020540Written as recombinant flt3 ligand
- flt3L in Treating Patients With Acute Myeloid LeukemiaCompletedPhase 3Eastern Cooperative Oncology GroupNCT00006223Written as recombinant flt3 ligand
- Flt3L in Treating Patients With Metastatic Colorectal CancerCompletedPhase 1Duke UniversityNCT00003431Written as recombinant flt3 ligand
Given in every arm · 3 — flt3 ligand protein is usual care beside what is tested
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsActive, not recruitingPhase 1University of Southern CaliforniaNCT04616248Written as Recombinant Flt3 Ligand
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04930783Written as CDX-301
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedPhase 1Celldex TherapeuticsNCT03329950Written as CDX-301
Codes
What other systems call flt3 ligand protein · ClinicalTrials.gg INT003766
- MeSH (NLM) C084881flt3 ligand proteinOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C084881 | flt3 ligand protein | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.